LUX Lung Special Access Scheme Australia Named Patient Use (NPU)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Registration Number
- NCT01209650
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The program will provide early access to the investigational drug BIBW 2992 to treat patients with advanced NSCLC who have failed at least 12 weeks on erlotinib or gefitinib.
The Compassionate Use Programme will also provide additional safety and efficacy information on BIBW 2992 use.
Named Patient Use (NPU)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- APPROVED_FOR_MARKETING
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
1200.47.1 Boehringer Ingelheim Investigational Site
🇦🇺North Ryde, New South Wales, Australia